EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Loss of O6‐Methylguanine‐DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms

Mark G Evans, Joanne Xiu, Sourat Darabi, Anthony Crymes, Adam Bedeir, David A Bryant, Matthew J Oberley, Michael J Demeure iD

World Journal of Surgery · 2025

DOI: 10.1002/wjs.12471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Surgery, 2025. Verfasst von Mark G Evans und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pathology and Clinical and Translational Research, Caris Life Sciences, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Tumor Suppressor Proteins, DNA Repair Enzymes, DNA Modification Methylases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A recent prospective phase II study (ECOG‐ACRIN E2211) demonstrated that MGMT deficiency was associated with a significant response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine neoplasms (NENs); however, routine MGMT analysis in NENs was not recommended. Our study sought to demonstrate whether loss of MGMT protein expression is associated with improved overall survival (OS) in patients receiving CAPTEM for NENs from various tumor sites. Materials and Methods Paraffin‐embedded tumor samples were evaluated by immunohistochemistry (IHC) using an MGMT monoclonal antibody. Intact MGMT protein expression (i.e., IHC positivity) was defined as any staining intensity (> 1+) in ≥ 36% of neoplastic cells according to an internal validation study. IHC and pyrosequencing for MGMT promotor methylation was performed in an independent cohort of 58 NENs. Real‐world OS was extrapolated from insurance claims data with Kaplan–Meier estimates from the date of first CAPTEM administration to the last date of contact.

Results

The study cohort included 80 patients (42 men and 38 women) with a median age of 57 years (range: 19–89). They had various NENs (33 pancreatic, 17 intestinal, 7 pulmonary, 8 other, and 15 of unknown origin) treated with CAPTEM. The median OS for the 48 patients with MGMT negative tumors was 31 months compared to 17.5 months for the 32 patients whose tumors were MGMT positive by IHC (HR: 1.75 [95% CI: 1.066–2.87] and p = 0.025). IHC results from the independent cohort of 58 NENs showed only 57% concordance with pyrosequencing results.

Conclusions

MGMT promotor status by IHC may be a clinically useful indicator that predicts improved OS for NENs treated with CAPTEM, but IHC does not reliably correlate with the findings of MGMT promoter methylation by pyrosequencing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsTumor Suppressor ProteinsDNA Repair EnzymesDNA Modification MethylasesDacarbazineAntineoplastic Combined Chemotherapy ProtocolsHumansTemozolomideMaleFemaleMiddle AgedCapecitabineImmunohistochemistryAdultAgedYoung AdultAged, 80 and overTreatment OutcomeBiomarkers, TumorDNA Methylation

Stichwörter der Autor:innen

MGMT immunohistochemistrycapecitabineneuroendocrine tumorstemozolomide

Substanzen

TemozolomideCapecitabineTumor Suppressor ProteinsDNA Repair EnzymesMGMT protein, humanDNA Modification MethylasesDacarbazineBiomarkers, Tumor

Autor:innen und Institutionen

  • Departments of Pathology and Clinical and Translational Research, Caris Life Sciences, Phoenix, Arizona, USA.
  • Precision Medicine Program, Hoag Family Cancer Institute, Newport Beach, California, USA.
  • Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Basis Phoenix High School, Phoenix, Arizona, USA.
  • Translational Genomics Research Institute, Phoenix, Arizona, USA.

ORCID-Profile: Michael J Demeure

Zitieren

APA

Evans, M. G., Xiu, J., Darabi, S., Crymes, A., Bedeir, A., Bryant, D. A., Oberley, M. J., & Demeure, M. J. (2025). Loss of O6‐Methylguanine‐DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms. World Journal of Surgery. https://doi.org/10.1002/wjs.12471

Vancouver

Evans MG, Xiu J, Darabi S, Crymes A, Bedeir A, Bryant DA, et al. Loss of O6‐Methylguanine‐DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms. World Journal of Surgery. 2025. doi:10.1002/wjs.12471

BibTeX
@article{Evans2025,
  author = {Evans, Mark G and Xiu, Joanne and Darabi, Sourat and Crymes, Anthony and Bedeir, Adam and Bryant, David A and Oberley, Matthew J and Demeure, Michael J},
  title = {Loss of O6‐Methylguanine‐DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms},
  journal = {World Journal of Surgery},
  year = {2025},
  doi = {10.1002/wjs.12471}
}
Kostenlos starten →